肺炎克雷伯菌
医学
重症监护医学
重症监护
抗生素耐药性
抗菌剂
抗生素
临床微生物学
梅德林
微生物学
生物
生物化学
大肠杆菌
基因
作者
Pablo Vidal,Ignacio Martín‐Loeches,Alejandro Rodríguez,Germán Bou,Rafael Cantón,Emili Dı́az,Carmen de la Fuente,J Torre-Cisneros,Francisco Xavier Nuvials,Miguel Salavert,Gerardo Aguilar,M. Nieto,Paula Ramírez,Marcio Borges,Cruz Soriano,Ricard Ferrer,Emilio Maseda,Rafael Zaragoza
出处
期刊:Antibiotics
[MDPI AG]
日期:2022-08-27
卷期号:11 (9): 1160-1160
被引量:8
标识
DOI:10.3390/antibiotics11091160
摘要
Infections due to Klebsiella pneumoniae have been increasing in intensive care units (ICUs) in the last decade. Such infections pose a serious problem, especially when antimicrobial resistance is present. We created a task force of experts, including specialists in intensive care medicine, anaesthesia, microbiology and infectious diseases, selected on the basis of their varied experience in the field of nosocomial infections, who conducted a comprehensive review of the recently published literature on the management of carbapenemase-producing Enterobacterales (CPE) infections in the intensive care setting from 2012 to 2022 to summarize the best available treatment. The group established priorities regarding management, based on both the risk of developing infections caused by K. pneumoniae and the risk of poor outcome. Moreover, we reviewed and updated the most important clinical entities and the new antibiotic treatments recently developed. After analysis of the priorities outlined, this group of experts established a series of recommendations and designed a management algorithm.
科研通智能强力驱动
Strongly Powered by AbleSci AI